NEW MJ NEWS

Cresco Labs Reports Continued Trend of Financial Improvement with First Quarter 2024 Financial Results

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the first quarter ended March 31, 2024. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here.

First Quarter 2024 Highlights

First quarter revenue of $184 million, flat year-over-year, excluding the impact from strategic divestitures aimed to drive profitability.

Gross profit of $92 million. Adjusted gross profit1 of $95 million up 7% year-over-year; and an Adjusted gross margin1 of 51% of revenue, a 580 bps improvement.

SG&A of $54 million. Reduced Adjusted SG&A1 by 24% year-over-year to $52 million, or 28% of revenue.

First quarter income before income taxes of $16 million, net loss of $2 million.

First quarter Adjusted EBITDA1 of $53 million, up 82% year-over-year; and Adjusted EBITDA margin1 of 29%, a 1,380 bps improvement.

$36 million in operating cash flow up 1,000% year-over-year. $33 million in Free Cash Flow1.

Retained the No. 1 share position in Illinois, Pennsylvania and Massachusetts2.

1

See “Non-GAAP Financial Measures” at the end of this press release for more information regarding the Company’s use of non-GAAP financial measures.

2

According to BDSA.

Management Commentary

“I want to thank the Cresco team for taking our learnings from the Year-of-the-Core, making them a part of our DNA and producing such a strong start to 2024. The continued development of our teams’ capabilities and our relentless focus on efficient execution is leading to very strong performance across our retail and branded product business resulting in a 10x increase in operating cash flow year-over-year. This is just the start, with upcoming adult use catalysts in Ohio and potential catalysts in Florida and Pennsylvania we have the ability to generate significant operating leverage and additional cash flow going forward.

I also want to thank the team for continuing Cresco’s leadership on cannabis reform. The recently announced potential federal rescheduling will fundamentally change the future for cannabis and all of its stakeholders. The team is fulfilling our vision of being the most important company in cannabis and leading the development of the most responsible, respectable and robust industry possible,” said Charles Bachtell, CEO of Cresco Labs.

Balance Sheet, Liquidity and Other Financial Information

As of March 31, 2024, current assets were $285 million, including cash, cash equivalents and restricted cash of $125 million. The Company had senior secured term loan debt, net of discount and issuance costs, of $387 million and a mortgage loan, net of discount and issuance costs of $18 million.

Total shares on a fully converted basis to Subordinate Voting Shares were 475,235,515 as of March 31, 2024.

Conference Call and Webcast

The Company will host a conference call and webcast to discuss its financial results on Wednesday, May 15, 2024, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 1-833-470-1428 (US Toll Free) or 1-404-975-4839 (US Local), providing access code 897519. Archived access to the webcast will be available for one year on Cresco Labs’ investor website.

Consolidated Financial Statements

The financial information reported in this press release is based on unaudited management prepared financial statements for the quarter ended March 31, 2024. These financial statements have been prepared in accordance with U.S. GAAP. The Company expects to file its unaudited condensed interim consolidated financial statements for the quarter ended March 31, 2024, on SEDAR+ and EDGAR on or about May 15, 2024. Accordingly, such financial information may be subject to change. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR+ and EDGAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company’s financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company’s filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission, for any purposes, that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company’s audited financial statements for the year ended December 31, 2023, previously filed on SEDAR+ and EDGAR.

Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the “Non-GAAP Financial Measures” section below for more detailed information.

Non-GAAP Financial Measures

This release reports its financial results in accordance with U.S. GAAP and includes certain non-GAAP financial measures that do not have standardized definitions under U.S. GAAP. The non-GAAP measures include: Earnings before interest, taxes, depreciation and amortization (“EBITDA”); Adjusted EBITDA; Adjusted EBITDA margin; Adjusted gross profit; Adjusted gross profit margin; Adjusted selling, general and administrative (“Adjusted SG&A”), Adjusted SG&A margin; and Free Cash Flow are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company defines these non-GAAP financial measures as follows: EBITDA as net loss (income) before interest, taxes, depreciation and amortization; Adjusted EBITDA as EBITDA less other income, net, adjustments for acquisition and non-core costs, impairment and share-based compensation; Adjusted EBITDA Margin as Adjusted EBITDA divided by revenues, net; Adjusted gross profit as gross profit less adjustments for acquisition and non-core costs; Adjusted gross profit margin as Adjusted gross profit divided by revenues, net; Adjusted SG&A as SG&A less adjustments for acquisition and non-core costs; Adjusted SG&A margin as Adjusted SG&A divided by revenues, net; and Free Cash Flow as Net cash (used in) provided by operating activities less purchases of property and equipment and proceeds from tenant improvement allowances. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

About Cresco Labs Inc.

Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2023, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Cresco Labs Inc.

Financial Information and Non-GAAP Reconciliations

(All amounts expressed in thousands of U.S. Dollars)

Unaudited Consolidated Statements of Operations

For the Three Months Ended March 31, 2024, December 31, 2023 and March 31, 2023

For the Three Months Ended

($ in thousands)

March 31,
2024

December 31,
2023

March 31,
2023

Revenues, net

$

184,295

$

188,237

$

194,202

Cost of goods sold

92,083

92,091

108,322

Gross profit

92,212

96,146

85,880

Gross profit %

50.0

%

51.1

%

44.2

%

Operating expenses:

Selling, general and administrative

54,013

56,767

71,897

Share-based compensation

3,614

2,278

6,124

Depreciation and amortization

5,422

9,978

4,273

Impairment loss

24

Total operating expenses

63,049

69,047

82,294

Income from operations

29,163

27,099

3,586

Other income (expense), net:

Interest expense, net

(14,071

)

(14,331

)

(15,548

)

Other income, net

856

50

959

Total other expense, net

(13,215

)

(14,281

)

(14,589

)

Income (loss) before income taxes

15,948

12,818

(11,003

)

Income tax expense

(18,003

)

(7,950

)

(16,809

)

Net (loss) income1

$

(2,055

)

$

4,868

$

(27,812

)

1 Net (loss) income includes amounts attributable to non-controlling interests.

Cresco Labs Inc.

Unaudited Reconciliation of Gross Profit to Adjusted Gross Profit (Non-GAAP)

For the Three Months Ended March 31, 2024, December 31, 2023 and March 31, 2023

For the Three Months Ended

($ in thousands)

March 31,
2024

December 31,
2023

March 31,
2023

Revenues, net

$

184,295

$

188,237

$

194,202

Cost of goods sold1

92,083

92,091

108,322

Gross profit

$

92,212

$

96,146

$

85,880

Cost of goods sold adjustments for acquisition and other non-core costs

2,662

3,576

2,819

Adjusted gross profit (Non-GAAP)

$

94,874

$

99,722

$

88,699

Adjusted gross profit % (Non-GAAP)

51.5

%

53.0

%

45.7

%

1 Production (cultivation, manufacturing and processing) costs related to products sold during the period.

Cresco Labs Inc.

Summarized Consolidated Statements of Financial Position

As of March 31, 2024 and December 31, 2023

($ in thousands)

March 31,
2024

December 31,
2023

(unaudited)

Cash, cash equivalents and restricted cash

$

124,901

$

108,520

Other current assets

160,182

169,567

Property and equipment, net

359,984

368,308

Intangible assets, net

298,069

296,966

Goodwill

279,697

279,697

Other non-current assets

137,232

135,409

Total assets

$

1,360,065

$

1,358,467

Total current liabilities

$

209,154

$

200,242

Total non-current liabilities

730,939

730,158

Total shareholders’ equity

419,972

428,067

Total liabilities and shareholders’ equity

$

1,360,065

$

1,358,467

Cresco Labs Inc.

Unaudited Reconciliation of SG&A to Adjusted SG&A (Non-GAAP)

For the Three Months Ended March 31, 2024, December 31, 2023 and March 31, 2023

For the Three Months Ended

($ in thousands)

March 31,
2024

December 31,
2023

March 31,
2023

Selling, general and administrative

$

54,013

$

56,767

$

71,897

Adjustments for acquisition and other non-core costs

2,297

2,242

4,041

Adjusted SG&A (Non-GAAP)

$

51,716

$

54,525

$

67,856

Adjusted SG&A % (Non-GAAP)

28.1

%

29.0

%

34.9

%

Cresco Labs Inc.

Unaudited Reconciliation of Net Income to Adjusted EBITDA (Non-GAAP)

For the Three Months Ended March 31, 2024, December 31, 2023 and March 31, 2023

For the Three Months Ended

($ in thousands)

March 31,
2024

December 31,
2023

March 31,
2023

Net (loss) income1

$

(2,055

)

$

4,868

$

(27,812

)

Depreciation and amortization

15,331

20,252

12,961

Interest expense, net

14,071

14,331

15,548

Income tax expense

18,003

7,950

16,809

EBITDA (Non-GAAP)

$

45,350

$

47,401

$

17,506

Other income, net

(856

)

(50

)

(959

)

Adjustments for acquisition and other non-core costs

4,470

4,434

5,671

Impairment loss

24

Share-based compensation

4,197

3,017

7,062

Adjusted EBITDA (Non-GAAP)

$

53,161

$

54,826

$

29,280

1 Net (loss) income includes amounts attributable to non-controlling interests.

Cresco Labs Inc.

Unaudited Summarized Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2024, December 31, 2023 and March 31, 2023

For the Three Months Ended

($ in thousands)

March 31,
2024

December 31,
2023

March 31,
2023

Net cash provided by (used in) operating activities

36,471

$

(3,301

)

$

3,270

Net cash (used in) provided by investing activities

(5,677

)

2,609

(20,668

)

Net cash used in financing activities

(11,149

)

(3,782

)

(13,635

)

Effect of foreign currency exchange rate changes on cash and cash equivalents

(13

)

(22

)

(25

)

Net change in cash and cash equivalents and restricted cash

$

19,632

$

(4,496

)

$

(31,058

)

Cash and cash equivalents and restricted cash, beginning of period

108,520

113,016

121,510

Cash and cash equivalents and restricted cash, end of period

$

128,152

$

108,520

$

90,452

Cresco Labs Inc.

Unaudited Reconciliation of Operating Cash Flow to Free Cash Flow (Non-GAAP)

For the Three Months Ended March 31, 2024, December 31, 2023 and March 31, 2023

For the Three Months Ended

($ in thousands)

March 31,
2024

December 31,
2023

March 31,
2023

Net cash provided by (used in) operating activities

$

36,471

$

(3,301

)

$

3,270

Purchases of property and equipment

(3,782

)

(4,818

)

(20,546

)

Proceeds from tenant improvement allowances

478

1,147

437

Free Cash Flow (Non-GAAP)

$

33,167

$

(6,972

)

$

(16,839

)

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515589627/en/

Contacts

Media
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
312-953-2767

Investors
TJ Cole, Cresco Labs
SVP, Corporate Development & Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$NTRR Setting New Milestones in Colorado and Cannabis Industry

NTRR: Banking Breakthrough in Colorado a New Milestone in Booming Cannabis Industry’s…

AgraFlora Organics International Inc. (AGRA) (AGFAF) To Architect Onsite Farm-Gate Retail Facilities

AgraFlora Organics To Architect Onsite Farm-Gate Retail Facilities at LPs in London…

AbbVie Inc. (ABBV) Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients

AbbVie Announces Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with…

Grow Capital, Inc (GRWC) Names Award-Winning Businessman and Author Terry Kennedy as Chief Executive Officer

Grow Capital, Inc Names Award-Winning Businessman and Author Terry Kennedy as Chief…